
Affimed prices public offering to finance NK cell trials
German Affimed N.V. has priced its previously announced public offering of 22,500,000 common shares at a $4.00 per common share. A 30-day...

$50m for London CHARM Therapeutics for deep minded folding expertise
London based CHARM Therapeutics rushes into the 3D deep-learning space with a $50M Series A financing co-led by F-Prime Capital and OrbiMed, with...

Meat consumption must fall by at least 75 percent
The study from lead author Prof. Dr Matin Qaim reviews the current state of research on various aspects of meat consumption. In addition to the...

EU starts consultation on novel plant breeding methods
he EU Commission has launched its final consultation on the deregulation of new breeding techniques in agriculture. A study commissioned by the...

Ellipses Pharma licences SRB22 from SunRock Biopharma
Under the agreement, British Ellipses Pharma Ltd has been granted global rights to develop and commercialise SBR22 (which it renamed to EP0017) from...

Roche obtains special authorisation for bispecific antibody
Roches new developed immunotherapy is based on a bispecific antibody, which targets B-lymphocyte antigen CD20 and the CD3-T-cell receptor at the...

Cannabis players Canify AS and Bavaria Weed merge to form Canify AG
The merger combines Canify AS’s expertise in the production of pharna-grade medical cannabis with the market position of Bavaria Weed GmbH, as...